Organon & Co
OGN9.770USD
+0.020+0.21%
Market hours （ET）Quotes delayed by 15 min
2.52BMarket Cap
3.36P/E TTM
More Details of Organon & Co Company
Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. Its portfolio also includes VTAMA (tapinarof) cream, 1%, a nonbiologic, non-steroidal topical therapy, for treatment of mild, moderate, and severe plaque psoriasis in adults.
Company Info
Ticker SymbolOGN
Company nameOrganon & Co
IPO dateMay 14, 2021
CEOMr. Kevin Ali
Number of employees10000
Security typeOrdinary Share
Fiscal year-endMay 14
Address30 Hudson Street
CityJERSEY CITY
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code07302
Phone15514306000
Websitehttps://www.organon.com/
Ticker SymbolOGN
IPO dateMay 14, 2021
CEOMr. Kevin Ali
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin Ali
Mr. Kevin Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
282.73K
+13.67%
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
144.48K
+8.57%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
71.89K
+18.29%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
59.92K
+10.11%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
52.85K
+17.96%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
41.33K
+26.65%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Independent Director
Independent Director
2.00
--
Ms. Ramona A. Sequeira
Ms. Ramona A. Sequeira
Independent Director
Independent Director
--
--
Mr. Robert A. (Bob) Essner
Mr. Robert A. (Bob) Essner
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin Ali
Mr. Kevin Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
282.73K
+13.67%
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
144.48K
+8.57%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
71.89K
+18.29%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
59.92K
+10.11%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
52.85K
+17.96%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
41.33K
+26.65%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Women’s Health
463.00M
30.60%
Cardiovascular
274.00M
18.11%
Respiratory
236.00M
15.60%
Non-Opioid Pain, Bone and Dermatology
217.00M
14.34%
Other
182.00M
12.03%
Biosimilars
141.00M
9.32%
By RegionUSD
Name
Revenue
Proportion
United States
412.00M
27.23%
Europe and Canada
376.00M
24.85%
Asia Pacific and Japan
251.00M
16.59%
Latin America, Middle East, Russia and Africa
240.00M
15.86%
China
204.00M
13.48%
Other
30.00M
1.98%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Women’s Health
463.00M
30.60%
Cardiovascular
274.00M
18.11%
Respiratory
236.00M
15.60%
Non-Opioid Pain, Bone and Dermatology
217.00M
14.34%
Other
182.00M
12.03%
Biosimilars
141.00M
9.32%
Shareholding Stats
Updated: Mon, Jun 2
Updated: Mon, Jun 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.39%
BlackRock Institutional Trust Company, N.A.
11.12%
MFS Investment Management
4.07%
State Street Global Advisors (US)
3.45%
LSV Asset Management
3.07%
Other
66.90%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.39%
BlackRock Institutional Trust Company, N.A.
11.12%
MFS Investment Management
4.07%
State Street Global Advisors (US)
3.45%
LSV Asset Management
3.07%
Other
66.90%
Shareholder Types
Shareholders
Proportion
Investment Advisor
51.44%
Investment Advisor/Hedge Fund
19.39%
Hedge Fund
3.75%
Research Firm
2.31%
Pension Fund
1.95%
Sovereign Wealth Fund
0.78%
Bank and Trust
0.65%
Individual Investor
0.35%
Family Office
0.05%
Other
19.34%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
1525
209.67M
80.65%
-45.17M
2025Q1
1611
213.21M
82.04%
-52.34M
2024Q4
1647
218.39M
84.67%
-40.43M
2024Q3
1625
211.80M
82.26%
-47.57M
2024Q2
1676
208.67M
81.14%
-51.47M
2024Q1
1700
205.29M
80.30%
-45.21M
2023Q4
1767
202.90M
79.38%
-24.07M
2023Q3
1835
205.61M
80.45%
-25.35M
2023Q2
2016
205.94M
80.75%
-21.55M
2023Q1
2044
204.79M
80.50%
-21.41M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
29.61M
11.39%
-704.86K
-2.33%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
28.91M
11.12%
-948.87K
-3.18%
Mar 31, 2025
MFS Investment Management
10.58M
4.07%
+827.89K
+8.49%
Mar 31, 2025
State Street Global Advisors (US)
8.98M
3.45%
-358.52K
-3.84%
Mar 31, 2025
LSV Asset Management
7.98M
3.07%
+455.70K
+6.06%
Mar 31, 2025
Sound Shore Management, Inc.
4.98M
1.91%
+8.42K
+0.17%
Mar 31, 2025
Nordea Funds Oy
4.85M
1.87%
-1.89M
-28.08%
Mar 31, 2025
DePrince, Race & Zollo, Inc.
4.65M
1.79%
-78.17K
-1.65%
Mar 31, 2025
Geode Capital Management, L.L.C.
4.52M
1.74%
+257.09K
+6.03%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
4.17M
1.6%
+884.26K
+26.92%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
SPDR S&P Pharmaceuticals ETF
3.68%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.61%
First Trust NASDAQ Pharmaceuticals ETF
1.89%
Invesco S&P SmallCap Health Care ETF
1.8%
KFA Value Line Dynamic Core Equity Index ETF
1.51%
Global X SuperDividend U.S. ETF
1.36%
Alger Russell Innovation ETF
1.3%
iShares U.S. Pharmaceuticals ETF
1.27%
Amplify Cash Flow Dividend Leaders ETF
1.22%
Amplify Cash Flow High Income ETF
1.21%
View more
SPDR S&P Pharmaceuticals ETF
Proportion3.68%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.61%
First Trust NASDAQ Pharmaceuticals ETF
Proportion1.89%
Invesco S&P SmallCap Health Care ETF
Proportion1.8%
KFA Value Line Dynamic Core Equity Index ETF
Proportion1.51%
Global X SuperDividend U.S. ETF
Proportion1.36%
Alger Russell Innovation ETF
Proportion1.3%
iShares U.S. Pharmaceuticals ETF
Proportion1.27%
Amplify Cash Flow Dividend Leaders ETF
Proportion1.22%
Amplify Cash Flow High Income ETF
Proportion1.21%
Dividend
A total of
1.03B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Feb 13, 2025
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 13, 2025 going ex on Feb 24, 2025
Feb 24, 2025
Mar 13, 2025
Feb 24, 2025
Oct 31, 2024
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 12, 2024 going ex on Nov 12, 2024
Nov 12, 2024
Dec 12, 2024
Nov 12, 2024
Aug 06, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 12, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 12, 2024
Aug 16, 2024
May 02, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Jun 13, 2024 going ex on May 10, 2024
May 13, 2024
Jun 13, 2024
May 10, 2024
Feb 15, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 14, 2024 going ex on Feb 23, 2024
Feb 26, 2024
Mar 14, 2024
Feb 23, 2024
Nov 02, 2023
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 14, 2023 going ex on Nov 10, 2023
Nov 13, 2023
Dec 14, 2023
Nov 10, 2023
Aug 08, 2023
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 14, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 14, 2023
Aug 17, 2023
May 04, 2023
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Jun 15, 2023 going ex on May 12, 2023
May 15, 2023
Jun 15, 2023
May 12, 2023
Feb 16, 2023
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 16, 2023 going ex on Feb 24, 2023
Feb 27, 2023
Mar 16, 2023
Feb 24, 2023
Nov 03, 2022
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 15, 2022 going ex on Nov 10, 2022
Nov 14, 2022
Dec 15, 2022
Nov 10, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
